跳至主要内容
临床试验/CTRI/2021/03/031918
CTRI/2021/03/031918招募中2 期

Prospective study to assess the feasibility of neoadjuvant chemoradiation with concurrent gemcitabine/capecitabine followed by surgery in locally advanced gall bladder cancer and its effect on peripheral immune response and Quality of life

one0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
one

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Histological proven case of gall bladder cancer
  • 2.Locally advanced gall bladder tumors staged as T3/T4, N1/N2 as per the 8th edition of TNM classification of the American Joint Committee on Cancer, with nodes along the common hepatic artery, cystic duct, hepatoduodenal ligament, periportal, peripancreatic and and periduodenal nodes, or T4 tumors that had >2 cm liver invasion.
  • 3.Normal hematological, renal and hepatic functions (serum bilirubin <3 mg/dl).

排除标准

  • 1.Age < 18 years
  • 2.History of prior radiotherapy and chemotherapy
  • 3.H/o prior malignancy
  • 4.Unwilling for written informed consent and follow-up
  • 5.Patients with retroperitoneal nodes
  • 6.Distant metastasis
  • 7.Major medical illness or psychiatric impairment that will prevent completion of protocol or would interfere with follow-up

研究者

发起方
one

相似试验